MEA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
The Middle East and Africa lung cancer diagnostics market is projected to register a substantial CAGR of 9.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation
Middle East and Africa Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Middle East and Africa lung cancer diagnostics market are:
• Rise in prevalence and incidence of lung cancer
• Increase in healthcare expenditure on cancer diagnosis and treatment
Market Players
Some of the major players operating in the Middle East and Africa lung cancer diagnostics market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott
• Quest Diagnostics Incorporated
• Bio-Rad Laboratories, Inc.
• Biocartis
• Danaher
• DiaSorin S.p.A
• LalPathLabs.com
• NanoString
• PerkinElmer Inc.
• QIAGEN
• Siemens Healthcare GmbH
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook